MedTrace Logo

Corticosteroid Treatment for Acute Respiratory Distress Syndrome

NCT02819453 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 105

Last updated 2021-07-02

No results posted yet for this study

Summary

It is acknowledged that IL-18, as a product of the inflammasome, is involved in host defence against viral and bacterial stimuli by modulating the immune response. The aim of this study was to determine IL-18 levels in serum of patients with acute respiratory distress syndrome and to investigate whether corticosteroid attenuate its levels. In addition, to explore the effect of corticosteroid therapy on the prognosis of ARDS.

Conditions

  • Acute Respiratory Distress Syndrome

Sponsors & Collaborators

  • Shanghai Pulmonary Hospital, Shanghai, China

    lead OTHER

Principal Investigators

  • Jin-Fu Xu, PhD · Shanghai Pulmonary Hospital, Shanghai, China

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2015-01-31
Primary Completion
2017-07-31
Completion
2017-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02819453 on ClinicalTrials.gov